Parallel Advisors LLC raised its position in shares of Humana Inc (NYSE:HUM) by 116.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,629 shares of the insurance provider’s stock after purchasing an additional 876 shares during the period. Parallel Advisors LLC’s holdings in Humana were worth $551,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. FMR LLC grew its stake in shares of Humana by 12.7% during the second quarter. FMR LLC now owns 12,212,514 shares of the insurance provider’s stock valued at $3,634,811,000 after buying an additional 1,374,030 shares during the last quarter. Glenmede Trust Co. NA grew its stake in shares of Humana by 153.7% during the second quarter. Glenmede Trust Co. NA now owns 500,266 shares of the insurance provider’s stock valued at $148,895,000 after buying an additional 303,080 shares during the last quarter. Unigestion Holding SA bought a new position in shares of Humana during the second quarter valued at about $79,340,000. LFA Lugano Financial Advisors SA bought a new position in shares of Humana during the second quarter valued at about $204,000. Finally, Bank of Montreal Can grew its stake in shares of Humana by 61.7% during the second quarter. Bank of Montreal Can now owns 413,429 shares of the insurance provider’s stock valued at $123,049,000 after buying an additional 157,752 shares during the last quarter. Institutional investors and hedge funds own 92.57% of the company’s stock.
NYSE HUM opened at $323.05 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $44.14 billion, a P/E ratio of 27.59, a price-to-earnings-growth ratio of 1.60 and a beta of 1.03. Humana Inc has a 1 year low of $231.90 and a 1 year high of $341.30.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.79 by $0.17. The company had revenue of $14.26 billion for the quarter, compared to analysts’ expectations of $14.16 billion. Humana had a return on equity of 17.43% and a net margin of 2.48%. During the same period last year, the firm earned $3.49 earnings per share. As a group, analysts anticipate that Humana Inc will post 14.18 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 25th. Investors of record on Monday, December 31st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 0.62%. Humana’s payout ratio is presently 17.08%.
A number of research analysts have recently issued reports on the company. SunTrust Banks reaffirmed a “hold” rating and set a $350.00 price objective on shares of Humana in a research note on Thursday, August 2nd. Piper Jaffray Companies raised their price objective on Humana from $326.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, July 6th. Cowen assumed coverage on Humana in a research note on Monday, September 17th. They set a “market perform” rating and a $372.00 price objective on the stock. Royal Bank of Canada reaffirmed a “hold” rating and set a $318.00 price objective on shares of Humana in a research note on Thursday, August 2nd. Finally, Bank of America raised their price objective on Humana from $338.00 to $375.00 and gave the company a “buy” rating in a research note on Thursday, August 2nd. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $339.79.
In related news, CEO Bruce D. Broussard sold 18,000 shares of the firm’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $328.66, for a total value of $5,915,880.00. Following the sale, the chief executive officer now directly owns 71,085 shares of the company’s stock, valued at $23,362,796.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Elizabeth D. Bierbower sold 3,092 shares of the firm’s stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $330.00, for a total value of $1,020,360.00. Following the completion of the sale, the insider now directly owns 14,289 shares in the company, valued at $4,715,370. The disclosure for this sale can be found here. Insiders sold 35,398 shares of company stock worth $11,574,961 over the last three months. 0.60% of the stock is owned by insiders.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Further Reading: Conference Calls
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.